UN organization claims the medicine, which has received approval as a coronavirus treatment from several health agencies, has 'no important effect' on improving survival chances

Medicine found to cut recovery time by five days on average, but no studies have shown it improves chances of surviving the coronavirus

Government backs Health Ministry in authorizing Gilead Sciences' donation of medicine

Company-led study finds those who who got medication for 5 days improved 65%, while there was no proven difference when getting it for 10 days; more details to be published

Researchers estimate death rate slightly higher among those taking hydroxychloroquine; separate study on remdesivir suggests benefit in treating COVID-19

Pharmaceutical company developing leading treatment for coronavirus; ClearSky cybersecurity outfit says Iran-connected hackers targeting COVID-19 researchers, including in Israel

FDA last week gave emergency approval to medicine produced by Gilead Sciences; it is believed to shorten illness time in some, but effect on mortality rates still unclear

Defense Department working on new blood-based screening that identifies body's immune response, may find illness 4 days earlier than current swab tests

In preliminary US trial Gilead Science’s remdesivir shortens recovery time by 4 days; cleared for use for hospitalized patients with 'severe disease'

Gilead Sciences says government medical agency to soon present results of trial testing remdesivir, which has been used at least once in Israel to treat virus